Abstract: An adenovirus comprising an E1A polypeptide comprising one or more modifications and comprising an E4orf6/7 polypeptide comprising one or more modifications is described. Compositions and kits comprising the modified adenoviruses are also described. Further described is a method of treating a proliferative disorder in a subject comprising administering to the subject an adenovirus comprising the E1A polypeptide comprising one or more modifications and comprising the E4orf6/7 polypeptide comprising one or more modifications.
Abstract: Methods for heart regeneration are provided. The invention provided herein includes methods of modulating proliferation of cardiomyocytes using small molecules and micro RNAs. In embodiments, the methods provided may be used to increase proliferation or cardiomyocytes. Further provided are methods to be used for the treatment of myocardial infarction.
Type:
Grant
Filed:
October 11, 2013
Date of Patent:
December 29, 2015
Assignee:
Salk Institute for Biological Studies
Inventors:
Aitor Aguirre, Ignacio Sancho-Martinez, Juan Carlos Izpisua-Belmonte
Abstract: The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.
Type:
Application
Filed:
July 7, 2015
Publication date:
December 24, 2015
Applicant:
SALK INSTITUTE FOR BIOLOGICAL STUDIES
Inventors:
RONALD M. EVANS, EIJI YOSHIHARA, MICHAEL R. DOWNES, RUTH T. YU, ANNETTE R. ATKINS
Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
Type:
Application
Filed:
June 5, 2015
Publication date:
December 3, 2015
Applicant:
Salk Institute for Biological Studies
Inventors:
Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
Abstract: Provided herein are methods and compositions for improving muscle performance and increasing endurance. Agonists of AMP-activated protein kinase (AMPK) and agonists of peroxisome proliferator-activated receptor delta (PPAR?) can be used in such treatments.
Type:
Grant
Filed:
December 29, 2008
Date of Patent:
November 24, 2015
Assignee:
Salk Institute for Biological Studies
Inventors:
Ronald M. Evans, Vihang A. Narkar, Reuben J. Shaw, Michael Downes, Ruth T. Yu
Abstract: Provided are methods of promoting browning of white adipose tissue (WAT) in a subject. Such methods can include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of fexaramine in combination with a therapeutically effective amount of a compound that mimics or increases sympathetic nervous system activity (e.g., one or more beta-adrenergic agonists and/or compounds that increase epinephrine secretion).
Type:
Application
Filed:
March 13, 2015
Publication date:
September 17, 2015
Applicants:
Salk Institute for Biological Studies, The Regents of the University of Michigan
Inventors:
Ronald M. Evans, Michael Downes, Annette Atkins, Sungsoon Fang, Jae Myoung Suh, Ruth T. Yu, Alan R. Saltiel
Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
Type:
Grant
Filed:
October 28, 2014
Date of Patent:
July 7, 2015
Assignee:
Salk Institute for Biological Studies
Inventors:
Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
Abstract: The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.
Type:
Application
Filed:
July 23, 2013
Publication date:
June 18, 2015
Applicants:
Xetrios Therapeutics, Inc., Salk Institute For Biological Studies
Inventors:
Greg E. Lemke, Lawrence C. Fritz, Benedikt Vollrath, Carla V. Rothlin
Abstract: The present invention relates to mutants of the plant aminotransferase VAS1 and to transgenic plants expressing said mutant protein that exhibit a modulated response to shade. In certain embodiments, the mutations of VAS1 uncouple VAS1 metabolic coordination of auxin and ethylene homeostasis, so that reduction of auxin is no longer linked (via VAS1) to reduction of ethylene. Such uncoupling allows for the generation of plants carrying a VAS1 mutant transgene that demonstrate a modulated response to shade, for example, less hypocotyl growth.
Type:
Application
Filed:
December 4, 2014
Publication date:
June 18, 2015
Applicant:
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
Inventors:
Joseph Noel, Joanne Chory, Yongxia Guo, Zuyu Zheng
Abstract: Provided herein are methods and compositions relating to the synthesis of isoprenoid diphosphates using a mutated isopentenyl phosphate kinase.
Abstract: Cyclic CRF antagonist peptides having improved properties of “drugability”. The peptides are 33 residues in length with a lactam bond between the residues in position 22 and 25; however, they may be N-terminally shortened by up to 3 residues.
Abstract: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERR? activity to the subject. Such agents can include one or more ERR? agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).
Type:
Application
Filed:
January 15, 2015
Publication date:
April 30, 2015
Applicant:
Salk Institute for Biological Studies
Inventors:
Vihang A. Narkar, Michael Downes, Ruth T. Yu, Ronald M. Evans
Abstract: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the ?Klotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
Type:
Grant
Filed:
February 10, 2014
Date of Patent:
April 7, 2015
Assignees:
Salk Institute for Biological Studies, New York University
Inventors:
Moosa Mohammadi, Regina M. Goetz, Ronald M. Evans, Michael Downes, Jae Myoung Suh
Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.
Type:
Application
Filed:
October 28, 2014
Publication date:
March 5, 2015
Applicant:
SALK INSTITUTE FOR BIOLOGICAL STUDIES
Inventors:
JOHAN W. JONKER, MICHAEL DOWNES, RONALD M. EVANS, JAE MYOUNG SUH
Abstract: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERR? activity to the subject. Such agents can include one or more ERR? agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).
Type:
Grant
Filed:
March 1, 2012
Date of Patent:
February 24, 2015
Assignee:
Salk Institute for Biological Studies
Inventors:
Vihang A. Narkar, Michael Downes, Ruth T. Yu, Ronald M. Evans
Abstract: The present disclosure relates to chimeric polypeptide having TGF-beta activity, nucleic acids encoding the polypeptides, and host cells for producing the polypeptides.
Type:
Grant
Filed:
February 24, 2010
Date of Patent:
February 10, 2015
Assignees:
The Salk Institute for Biological Studies, joint Center for Biosciences
Inventors:
Senyon Choe, George Allendorph, Michael J. Isaacs
Abstract: The relationship between F-box proteins and proteins involved in the ethylene response in plants is described. In particular, F-box proteins may bind to proteins involved in the ethylene response and target them for degradation by the ubiquitin/proteasome pathway. The transcription factor EIN3 is a key transcription factor mediating ethylene-regulated gene expression and morphological responses. EIN3 is degraded through a ubiquitin/proteasome pathway mediated by F-box proteins EBF1 and EBF2. The link between F-box proteins and the ethylene response is a key step in modulating or regulating the response of a plant to ethylene. Described herein are transgenic plants having an altered sensitivity to ethylene, and methods for making transgenic plant having an altered sensitivity to ethylene by modulating the level of activity of F-box proteins. Methods of altering the ethylene response in a plant by modulating the activity or expression of an F-box protein are described.